Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • PhamAust AGM 2022
    • Company Research
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • PhamAust AGM 2022
    • Company Research
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Category Archives: News and Announcements 2021

December 15, Epichem Awarded DNDi Extension

News and Announcements 2021By PharmAust15/12/2021

December 13, Shareholder Update and Strategy

News and Announcements 2021By PharmAust13/12/2021

13

December 1, Demonstration Batch Small MPL Tablets Completed

Financial Reports 2017, News and Announcements 2021By PharmAust01/12/2021

211201_DemonstrationTabletsComplete

December 1, Top 20 Shareholders

News and Announcements 2021, Top 20 ShareholdersBy PharmAust01/12/2021

211201_Top_20_Holders_Report

November 17, FightMND and COVID-19 Trials on Track

News and Announcements 2021By PharmAust17/11/2021

November 17,

November 15, New Zealand Joins Phase 2B Pet Dog Trial

Financial Reports 2017, News and Announcements 2021By PharmAust15/11/2021

211115_NZ Trial Centres

November 1, Top 20 Shareholders

News and Announcements 2021By PharmAust01/11/2021

211031_Top20Shareholders

October 21, AGM Presentation

News and Announcements 2021By PharmAust21/10/2021

211121_AGM_Presentation

October 21, MPL Demonstration Batch for Human Trials Complete

News and Announcements 2021By PharmAust21/10/2021

211021_MPL DemoBatch Complete

October 18, Canine Trial Update

News and Announcements 2021By PharmAust18/10/2021

211018_CanineTrialUpdate

→12345→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

Facebook
Facebook
fb-share-icon
Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Nov

Newly appointed CEO of clinical-stage biopharmaceutical development company PharmAust Dr Michael Thurn says the company is well-positioned to capitalise on the lucrative rare diseases market.
#ad #ASX @PharmAust

Reply on Twitter 1727114614402437408 Retweet on Twitter 1727114614402437408 3 Like on Twitter 1727114614402437408 6 Twitter 1727114614402437408
pharmaust PharmAust @pharmaust ·
22 Nov

Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market

Reply on Twitter 1727116385040716075 Retweet on Twitter 1727116385040716075 4 Like on Twitter 1727116385040716075 8 Twitter 1727116385040716075
pharmaust PharmAust @pharmaust ·
21 Nov

PharmAust has released a formal video of its recent non-deal #roadshow presentation.

🎥 https://vimeo.com/884693453/12f5b671d2

Reply on Twitter 1726832212392518124 Retweet on Twitter 1726832212392518124 1 Like on Twitter 1726832212392518124 4 Twitter 1726832212392518124
Load More

Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top